Not available
Quote | Ra Pharmaceuticals Inc. (NASDAQ:RARX)
Last: | $47.99 |
---|---|
Change Percent: | -0.04% |
Open: | $47.99 |
Close: | $47.99 |
High: | $48.01 |
Low: | $47.98 |
Volume: | 4,068,616 |
Last Trade Date Time: | 04/01/2020 04:47:15 am |
News | Ra Pharmaceuticals Inc. (NASDAQ:RARX)
Investment Thesis The patent disputes over its leading revenue generator have taken its toll on Alexion Pharmaceuticals, Inc. ( ALXN ), with its share price lagging the peers as the company attempts to diversify the top-line. The recent acquisitions, driven by the rising cash flows and low...
This article is part of a series that provides an ongoing analysis of the changes made to Prem Watsa's 13F portfolio on a quarterly basis. It is based on Watsa's regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Prem Watsa's Fairfax Financial Holdings Portfolio series to g...
Message Board Posts | Ra Pharmaceuticals Inc. (NASDAQ:RARX)
Subject | By | Source | When |
---|---|---|---|
research indicates strong company here | edwardport | investorshub | 03/31/2020 11:52:03 PM |
znewcar1: RARX 101% v20M c45.64 f47M gap up then S@45.2 with EOD push | znewcar1 | investorshangout | 10/10/2019 8:23:38 PM |
Why is it up today, in volume and price? | AnotherInvestor | investorshub | 08/31/2018 4:53:46 PM |
This seems to be a bit oversold. | r clarke | investorshub | 12/12/2017 12:29:26 AM |
Up and up? | AD2000 | investorshub | 05/16/2017 1:32:14 AM |
News, Short Squeeze, Breakout and More Instantly...
Ra Pharmaceuticals Inc. Company Name:
RARX Stock Symbol:
NASDAQ Market:
Ra Pharmaceuticals Inc. Website:
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...
Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...